William E. Rote, Chief Research Officer at Travere Therapeutics, Inc. (TVTX), sold 60,000 shares at $40.10 ($2.4M) on 2025-12-24, disclosed to the SEC on 2025-12-29.
Scheduled sale ($2.4M) by Chief Research Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| TVTX | SELL | 2026-04-23 | $356K | — | Filing → |
| TVTX | SELL | 2026-02-03 | $409K | — | Filing → |
| TVTX | SELL | 2025-05-05 | $135K | — | Filing → |